Kymera Therapeutics Inc (NASDAQ: KYMR) is 41.64% higher on its value in year-to-date trading and has touched a low of $19.44 and a high of $53.27 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The KYMR stock was last observed hovering at around $45.71 in the last trading session, with the day’s gains setting it 847.76%.
Currently trading at $893.47K, the stock is -2.98% and 20.58% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.8 million and changing 3795631% at the moment leaves the stock 11.81% off its SMA200. KYMR registered 9.67% gain for a year compared to 6-month loss of 8.16%. The firm has a 50-day simple moving average (SMA 50) of $36.5888 and a 200-day simple moving average (SMA200) of $39.461224.
The stock witnessed a 53.19% gain in the last 1 month and extending the period to 3 months gives it a 46.09%, and is -3.82% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.04% over the week and 6.15% over the month.
Kymera Therapeutics Inc (KYMR) has around 188 employees, a market worth around $2.87B and $58.88M in sales. Profit margin for the company is -409.07%. Distance from 52-week low is 126.90% and -17.18% from its 52-week high. The company has generated returns on investments over the last 12 months (-28.03%).
with sales reaching $20.27M over the same period.The EPS is expected to shrink by -14.31% this year, but quarterly earnings will post 65.98% year-over-year. Quarterly sales are estimated to shrink -20.97% in year-over-year returns.
Kymera Therapeutics Inc (KYMR) Top Institutional Holders
251.0 institutions hold shares in Kymera Therapeutics Inc (KYMR), with institutional investors hold 114.75% of the company’s shares. The shares outstanding are 65.11M, and float is at 53.16M with Short Float at 14.26%. Institutions hold 111.66% of the Float.
The top institutional shareholder in the company is PRICE T ROWE ASSOCIATES INC /MD/ with over 6.39 million shares valued at $190.76 million. The investor’s holdings represent 8.7472% of the KYMR Shares outstanding. As of 2024-06-30, the second largest holder is BAKER BROS. ADVISORS LP with 6.0 million shares valued at $178.98 million to account for 8.2069 of the shares outstanding. The other top investors are ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC which holds 5.35 million shares representing 7.3234% and valued at over $159.71 million, while BVF INC/IL holds 7.0652 of the shares totaling 5.16 million with a market value of $154.08 million.
Kymera Therapeutics Inc (KYMR) Insider Activity
The most recent transaction is an insider sale by Ridloff Elena, the company’s Director. SEC filings show that Ridloff Elena sold 4,500 shares of the company’s common stock on Jun 11 ’25 at a price of $50.00 per share for a total of $0.23 million. Following the sale, the insider now owns 0.0 shares.
Still, SEC filings show that on Jun 03 ’25, Esposito Pamela (Director) disposed off 5,000 shares at an average price of $49.04 for $0.25 million. The insider now directly holds 0 shares of Kymera Therapeutics Inc (KYMR).
